Further experiments, such as hepatocyte cultivation in vitro or clinical studies, are required to fully elucidate the correlation between the NF-κB pathway and the mechanism of NAFLD, and to provide additional evidence regarding the protective effects of glutamine in NAFLD. The gene discussed is NFKB1; the disease is metabolic dysfunction-associated steatotic liver disease.